Find A Clinical Trial

Disease Type: Lung

Trial ID BLU-451-1
Sponsor ID Blueprint Medicines Corporation

A Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR Exon 20 Insertion Mutations

Trial ID Onc-392-001
Sponsor ID Preserve-001

Safety, Pharmacokinetics, and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase 1A/1B Study

Trial ID D9077C00001
Sponsor ID NEOCOAST-2

A Phase 2 Open-Label, Multicenter Randomized Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-Stage (II-IIIA) NSCLC

5 Locations
Trial ID CINC280AUS12
Sponsor ID GEOMETRY-N

A Phase 2 Trial of Neoadjuvant and Adjuvant Capmatinib in Participants with Stages IB-IIIA, N2, and Selected IIIB (T3N2 or T4N2) NSCLC with MET Exon 14 Skipping Mutation or High MET Amplification

5 Locations
Trial ID USOR 21320
Sponsor ID Genprex

A Phase 1/2 Open-Label Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Patients with Advanced, EGFR-Mutated, Metastatic NSCLC Who Have Progressed After Treatment with Osimertinib

1 Location
Trial ID NVL-520-01
Sponsor ID ARROS-1

A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and other Solid Tumors

Trial ID BGB-A317-A1217-301
Sponsor ID BeiGene

A Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Plus Concurrent Chemoradiation Followed by Ociperlimab Plus Tislelizumab or Tislelizumab Plus CCRT Followed by Tislelizumab Versus CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced, Unresectable NSCLC

1 Location
Trial ID M21-410
Sponsor ID AbbVie

A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with ABBV-514 as a Single Agent and in Combination with Pembrolizumab or Budigalimab

Trial ID BLU-701-1101
Sponsor ID Blueprint Medicines Corporation

A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.

1 Location
Trial ID NBF-006
Sponsor ID Nitto BioPharma

A Phase 1/1b Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF-006 in Patients with Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients with KRAS-Mutated Non-Small Cell Lung Cancer.